SaddleRock Capital Management LLC Invests $9.55 Million in IQVIA Holdings Inc. $IQV

SaddleRock Capital Management LLC bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, Holdings Channel reports. The fund bought 49,433 shares of the medical research company’s stock, valued at approximately $9,551,000. IQVIA makes up approximately 9.2% of SaddleRock Capital Management LLC’s portfolio, making the stock its 4th largest position.

A number of other institutional investors have also recently added to or reduced their stakes in IQV. International Assets Investment Management LLC purchased a new stake in IQVIA in the 4th quarter worth $27,000. Compass Financial Management LLC purchased a new position in IQVIA during the second quarter valued at $27,000. Gilpin Wealth Management LLC acquired a new stake in shares of IQVIA in the fourth quarter valued at about $27,000. CrossGen Wealth LLC purchased a new stake in shares of IQVIA during the fourth quarter worth about $28,000. Finally, Activest Wealth Management raised its position in shares of IQVIA by 590.0% during the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after purchasing an additional 118 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Up 0.2%

Shares of NYSE IQV opened at $260.30 on Tuesday. The stock has a market cap of $42.85 billion, a PE ratio of 32.30, a P/E/G ratio of 2.21 and a beta of 1.18. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $261.88. The company has a 50-day moving average of $214.97 and a 200 day moving average of $187.62.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its Board of Directors has approved a share repurchase program on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on IQV shares. Morgan Stanley reiterated an “equal weight” rating and issued a $200.00 price objective (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. TD Cowen increased their target price on IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Robert W. Baird raised their target price on IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Stifel Nicolaus lifted their price target on IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a research note on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $241.88.

Insider Buying and Selling

In other IQVIA news, insider Keriann Cherofsky sold 558 shares of the business’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. The trade was a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Bhavik Patel sold 1,855 shares of the company’s stock in a transaction on Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the sale, the insider owned 1,348 shares of the company’s stock, valued at approximately $317,143.96. The trade was a 57.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 12,913 shares of company stock worth $3,098,793. 1.70% of the stock is currently owned by corporate insiders.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.